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Abstract:  
The purpose of writing this review is Oral delivery is currently the gold standard in the pharmaceutical industry where 
it is regarded as the safest, most convenient and most economical method of drug delivery having the highest patient 
compliance. It is leads to development of orally disintegrating tablets. This disintegrates in the mouth in seconds 
without chewing and the need of water which is advantageous mainly for pediatrics, geriatrics and patients having 
difficulty in swallowing tablets and capsules. The prepared tablets were evaluated for hardness, friability, 
disintegration time and in vitro drug release ODTs are solid dosage forms containing medicinal substances which 
disintegrate rapidly, usually in a matter of seconds, when placed on the tongue. The aim of this article is to review the 
development of ODTs, challenges in formulation, new ODT technologies and evaluation methodologies, suitability of 
drug candidates, and future prospects.   
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INTRODUCTION (1) 
Oral drug delivery is currently the gold standard in the 
pharmaceutical industry where it is regarded as the 
safest, the most convenient and most economical 
method of drug delivery with the highest patient 
compliance. 
 
Oral route is the most preferred route of administration 
and tablet and capsules are the most preferred dosage 
forms, but several limitations of that kind of dosage 
forms like chocking and swelling discomfort in 
geriatric and pediatric patients. Orally disintegrating 
tablets have been developed and new ODT 
technologies compensate many pharmaceuticals and 
patients’ needs, ranging from enhanced life-cycle 
management to convenient dosing for pediatric, 
geriatric, and psychiatric patients with dysphasia 
.Over the past three decades, orally disintegrating 
tablets (ODTs) have gained considerable attention as a 
preferred alternative to conventional tablets and 
capsules due to better patient compliance . ODTs are 
being named as orodispersible, rapid-dissolving, 
mouth-dissolving, rapid-disintegrating tablets. There 
are some definitions that made by pharmacopeias and 
agency as follows: Orodispersible tablets have been 
placed in the mouth where they disperse fast before 
being swallowed and they are uncoated tablets. 
Orodispersible tablets disintegrate within 180 seconds 
when the disintegration tests have been conducted up 
to the test for disintegration of tablets. 
 
For most therapeutic agents used to produce systemic 
effects, the oral route still represents the preferred way 
of administration, owing to its several advantages and 
high patient compliance compared to many other 
routes2 . Tablets and hard gelatin capsules constitute a 
major portion of drug delivery systems that are 
currently available. However, many patient groups 
such as the elderly, children, and patients who are 
mentally retarded, uncooperative, nauseated, or on 
reduced liquid-intake/diets have difficulties 
swallowing these dosage forms. 
 
Although chewable tablets have been on the market 
for some time, they are not the same as the new ODTs. 
Patients for whom chewing is difficult or painful can 
use these new tablets easily. ODTs can be used easily 
in children who have lost their primary teeth but do not 
have full use of their permanent teeth. 
 
Recent market studies indicate that more than half of 
the patient population prefers ODTs to other dosage 
forms10 and most consumers would ask their doctors 
for ODTs (70%), purchase ODTs (70%), or prefer 
ODTs to regular tablets or liquids (>80%) 
 
MECHANISMS OF ODTs (2) 
ODTs involve the following mechanisms to achieve 
the desired fast dissolving characteristics: 
1. Water must quickly enter into the tablet matrix to 
cause rapid disintegration and instantaneous 
dissolution of the tablet. 
2. Incorporation of an appropriate disintegrating agent 
or highly water soluble excipients in the tablet 
formulation.  
3. There are some under mentioned mechanisms by 
which the tablet is broken down into the smaller 
particles and then subsequently result a solution or 
suspension of the drug. The mechanisms are-   
• High swellability of disintegration 
• Chemical reaction 
• Capillary action 
 
Advantages of ODTs(3) 
• No need of water to swallow the tablet.  
• Compatible with taste masking and have a 
pleasing mouth feel.   
• Can be easily administered to paediatric, 
• elderly and mentally disabled patients. 
• No residue in the oral cavity after administration.   
• Manufacturing of the tablets can be done  using 
conventional processing and packaging    
equipments at minimum cost.                       
• Allow high drug loading. 
• Accurate dose can be given as compared to 
liquids.   
• Dissolution and absorption of the drug is fast, 
offering a rapid onset of action.   
• Advantageous over liquid medication in terms of 
administration as well as transportation. 
 
  Disadvantages of ODTs(3) 
 
• ODT is hygroscopic in nature so must be keep in 
dry place 
• Some time it possesses mouth feeling. 
• It is also shows the fragile, effervescence granules 
property. 
• ODT requires special packaging for properly 
stabilization & 
• safety of stable product. 
 
Significance of ODTs (6),(10),(28) 
ODTs offer dual advantages of solid dosage forms and 
liquid dosage forms along with special features which 
include:  
• Accurate dosing: Being unit solid dosage forms, 
provide luxury of accurate dosing, easy 
portability and manufacturing, good physical and 
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chemical stability and an ideal alternative for 
pediatric and geriatric patients.  
• Enhanced bioavailability: Bioavailability of drugs 
is enhanced due to absorption from mouth, 
pharynx and esophagus.  
• Rapid action: Fast onset of therapeutic action as 
tablet gets disintegrated rapidly along with quick 
dissolution and absorption in oral cavity.  
• Patient compliance: No need of water to swallow 
the dosage form. Hence, it is convenient for 
patients who are traveling and do not have 
immediate access to water. • Ease of 
administration: Convenient to administer 
specially for geriatric, pediatric, mentally 
disabled and bed ridden patients who have 
difficulty in swallowing. 
• Obstruction free: No risk of suffocation in 
airways due to physical obstruction when 
swallowed, thus providing improved safety and 
compliance.  
• Enhanced palatability: Good mouth feel, 
especially for pediatric patients as taste masking 
technique is used to avoid the bitter taste of drug.           
 
Ideal characteristics of ODTs(25),(26) 
 ODTs should depict some ideal characteristics to 
distinguish them from traditional conventional dosage 
forms. Important desirable characteristics of these 
dosage forms include:  
• No water requirement for swallowing purpose but 
it should dissolve or disintegrate in the mouth 
usually within fraction of seconds.  
• Provide pleasant feeling in the mouth. 
• Be compatible with taste masking.  
 
Limitations of ODTs(4) 
• The tablets commonly have insufficient 
mechanical strength. Hence, conscientious 
handling is necessary.   
• The tablets may leave an unpalatable taste and 
grittiness in the oral cavity if not formulated 
properly.   
• Drugs which have large doses, can cause 
problems to formulate them into ODTs.   
• Patients who simultaneously take anticholinergic 
drugs are not suitable candidates for ODTs 
 
Bioequivalence(5),(6) 
Bioequivalence of ODTs has some challenges but in 
this part basic solutions to overcome these challenges 
were given. Active pharmaceutical ingredients that are 
formulated as ODTs should be dispersed or dissolved 
in the saliva, then directly absorbed via oral mucosa 
and/or absorbed through the gastrointestinal system. 
When defining the dissolution test conditions to prove 
both of the in-vitro and in-vivo bioequivalence of two 
formulations, the physiological conditions of the 
mouth should be considered. pH, flow rate, volume of 
the saliva and targeted population are the important 
factors that should be considered.  
 
There are several in-vivo studies for ODTs that 
conducted to prove bioequivalence of the ODTs, 
nevertheless BCS based biowaiver is also being 
considered for especially the active pharmaceutical 
ingredients are not absorbed via oral mucosa, but must 
be absorbed through the gastrointestinal system. But if 
this cannot be demonstrated, bioequivalence must be 
evaluated via in-vivo studies 
 
If the ODT is a generic/hybrid to an approved ODT 
reference medicinal product, the following 
recommendations regarding study design apply: 
• If the reference medicinal product can be taken 
with or without water, bioequivalence should be 
demonstrated without water as this condition best 
resembles the intended use of the formulation. 
This is especially important if the substance may 
be dissolved and partly absorbed in the oral 
cavity. If bioequivalence is demonstrated when 
taken without water, also bioequivalence can be 
assumed with ODT taken with water. 
• If the reference medicinal product is taken only in 
one way (e.g. only with water), bioequivalence 
should be shown in this condition (in a 
conventional two-way crossover design).  
• If the reference medicinal product is taken only in 
one way (e.g. only with water), and the test 
product is intended for additional ways of 
administration (e.g. without water), the 
conventional and the new method should be 
compared with the reference in the conventional 
way of administration (3 treatment, 3 period, 6 
sequence design). In studies evaluating ODTs 
without water, it is recommended to wet the 
mouth by swallowing 20 ml of water directly 
before applying the ODT on the tongue. It is 
recommended not to allow fluid intake earlier 
than 1 hour after administration 
 
Formulation Development of ODTs(7),(19) 
Selection of active pharmaceutical ingredient is one of 
the most important parameters to formulate ODTs. It 
should be dissolved in the oral cavity and absorbed. 
Also it shouldn’t have bitter taste. It is better if it is in 
low dose, small to moderate molecular weight, good 
solubility in water and/or saliva, non-ionized property 
in pH 5.5-7.4 and ability to be absorbed via oral 
mucosa. 
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Excipient selection is important for disintegrating the 
tablet immediately and also important for masking 
bitter taste. Main excipient groups are diluents; 
disintegrants that have different disintegrate 
mechanisms, flavors, and taste masking agents, 
sweeteners, binders, lyoprotectants, glidants and 
lubricants. To accomplish the challenges, specific 
excipients can be used in different ranges. 
 
TECHNIQUES FOR PREPARATION OF ODTs(7) 
The fast dissolving property of the ODTs requires 
quick ingress of water into tablet matrix thus requires 
some basic approaches such as maximizing the porous 
structure of the tablet, incorporation of suitable 
disintegrating agent and use of highly water-soluble 
excipients in the formulation. Excipients use in ODTs 
contain at least one superdisintegrant (having 
mechanism of wicking, swelling or both), a diluent, a 
lubricant and optionally a swelling agent, a 
permeabilizing agent, sweeteners and flavorings. 
 
Various preparation techniques have been developed 
on the basis of different principles, thus present 
different properties of ODTs by means of mechanical 
strength, stability, mouth feel, taste, swallowability, 
dissolution profile and bioavailability.  
 
Freeze drying/ Lyophilization (9) 
This process is based on solvent removal from a frozen 
drug solution or suspension which contains structure 
forming excipients. The process generally resulted as 
very light and highly porous form in nature. 
 
Spray drying(8) 
This process is based upon to use of a particulate 
support matrix prepared by spray drying. Support 
matrix and other components containing aqueous 
composition form a highly porous and fine powder, 
then disintegration and dissolution improve by adding 
effervescent components and finally spray dried to 
yield a porous powder. 
 
Molding (9) 
This process is achieved by using water soluble 
ingredients mostly sugars. Drug and excipients 
powder blend is pushed through a very fine screen then 
moistened with a hydroalcoholic solvent and moulded 
into tablets under pressure, the process ended by 
evaporating of the solvent by air drying. 
 
Phase transition process (8) 
In this process, tablets which contain sugar alcohols 
having high and low melting points are prepared by 
compressing; following heating to enhance bonding 
among particles resulted as sufficient hardness of 
tablets. 
 
Melt granulation(10) 
In this process powders are efficiently agglomerated 
by the use of binder which can be liquid or melting 
during the process by using high shear mixers, and 
temperature is raised above the melting point of the 
binder.  
 
Sublimation(11) 
For accomplishing this process some inert volatile 
substances like urea, camphor etc. is added to other 
tablet excipients and blend is compressed into tablet. 
Subsequently removal of volatile substances by 
sublimation generates a porous structure. 
 
Mass extrusion(11) 
This process based on softening of the active blend by 
using a solvent mixture of water soluble polyethylene 
glycol and methanol. Following expulsion of softened 
mass through the extruder or syringe to get a 
cylindrical shaped, they cut into segments by using 
heated blade to form tablets. 
 
Patented technologies for orally disintegrating 
drug delivery system(12) 
The various technologies are developed for the 
preparation of Orally Disintegrating Drug Delivery 
System that are:  
• Zydis  
• Lyoc  
• Wowtab  
• Flashtab  
• Durasolv  
• Orasolv  
• Frosta  
• AdvaTab  
• Flashdose  
• OraQuick  
• Nanocrystal Technology  
• Quick-Dis Technology  
• EFVDAS  
• Fast Melt  
• Multiflash  
 
Zydis® (Cardinal Health Inc.) (12) 
Zydis® was first marketed technology and introduced 
by R. P. Scherer Corporation (Cardinal Health, Inc.) in 
1986. Zydis tablet is produced by lyophilizing the drug 
in a matrix usually consisting of gelatin. The product 
is very lightweight and fragile and must be dispensed 
in a special blister pack. Zydis formulation is also self-
preserving because the final water concentration in the 
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freeze-dried product is too low to allow for microbial 
growth  
Disadvantages to the Zydis® technology-  
• Relatively expensive & time consuming 
manufacturing process.  
• Formulation is very lightweight and fragile.  
• Poor stability at higher temperatures and 
humidity & stress conditions.  
• A water insoluble drug can be incorporated 
only upto 400 mg per tablet or less. On the other hand 
water soluble drug can be incorporated only upto 60 
mg.  
 
The preferred drugs are water insoluble, low dose, 
chemically stable, small particle size and tasteless. The 
two most commonly used structural additives are 
gelatin and mannitol. Some other structural additives 
(e.g., starches, gums etc.) may be used depending on 
the properties of the active ingredient. The best 
physical characteristics are achieved by using a 
mixture of a water-soluble polymer and a crystalline 
sugar alcohol or amino acid. The polymer gives the 
strength and resilience while the crystalline 
component gives the hardness and texture. Polymers 
such as gelatin, dextran or alginates are added to 
impart strength during handling. These form a glossy 
and amorphous structure. Mannitol or sorbitol is added 
to impart crystallinity, elegance and hardness. Various 
gums may be added to prevent sedimentation of 
dispersed drug particles. Water is used as a medium to 
ensure the formation of a porous dosage form. 
Collapse protectants like glycine may be used to 
prevent shrinkage of dosage form during freeze drying 
and long-term storage. If necessary, suspending agents 
and pH adjusting agents may be used. 
 
Lyoc (Cephalon Corporation)(12)  
Lyoc technique was owned by Cephalon Corporation. 
Lyoc utilizes a freeze drying process but differ from 
Zydis in that the product is frozen on the freeze dryer 
shelves. The liquid solution or suspension preparation 
evolves fillers, thickening agents, surfactant, non-
volatile flavoring agents and sweeteners along with 
drug. This homogeneous liquid is placed in blister 
cavities and subjected to freeze drying. To prevent 
inhomogeneity by sedimentation during this process, 
these formulations require a large proportion of 
undissolved inert filler (mannitol), to increase the 
viscosity of the inprocess suspension. The high 
proportion of filler reduces the potential porosity of 
the dried dosage form and results in denser tablets with 
disintegration rates are comparable to loosely 
compressed fast melt formulations. 
 
Wowtab (Yamanouchi Pharma Technologies, Inc.) 
(12) 
Wowtab technology was developed by Yamanouchi 
Pharma Technologies. ‘Wow’ means ‘    without 
water’. The active ingredients may constitute upto 
50% w/w of the tablet. Here,   saccharides of both low 
and high Moldability are used to prepare the granules. 
Moldability is the capacity of a compound to be 
compressed. Highly Moldable substance has high 
compressibility and thus slow dissolution. The 
combination of high and low Moldability is used to 
produce tablets of adequate hardness & a rapidly 
melting strong tablet. Active ingredients are mixed 
with low Moldability saccharides and then granulated. 
 
Wowtab product can be packed in both into 
conventional bottle and blister      packs. This 
technology utilizes conventional granulation and 
tableting methods and used for both water-soluble and 
insoluble drugs. The manufacturing process involves 
granulating low-moldable sugars (e.g.mannitol, 
lactose, glucose, sucrose, and erythritol) that show 
quick dissolution characteristics with high moldable 
sugars (e.g. maltose, maltitol, and sorbitol). The result 
is a mixture of excipients that have fast-dissolving and 
highly moldable characteristics. 
 
Flashtab (Prographarm) (12),(15) 
Flashtab was developed by Prographarm. A 
disintegrating agent and a swelling agent are used in 
combination with coated taste-masked microgranules 
of drug. FlashTab involves coating a drug with a 
Eudragit polymer to provide rapid release of the drug 
in the stomach, and formulating this 
microencapsulated drug with an effervescent couple to 
produce a flash dispersal tablet. This technology 
includes granulation of excipients by wet or dry 
granulation method followed by compression into 
tablets. Disintegrating agents include 
polyvinylpyrrolidine or carboxy methyl cellulose and 
Swelling agents include carboxymethylcellulose, 
starch, modified starch, microcrystalline cellulose, 
carboxy methylated starch etc. These tablets have 
satisfactory physical resistance. Tablets containing 
hygroscopic materials can also be blister packed using 
high quality polyvinyl chloride or aluminum foils for 
providing the higher degree of moisture protection 
than normal polyvinyl chloride or polypropylene foils.  
 
Durasolv (Cima Labs, Inc.)(12)  
DuraSolv is Cima's second-generation fast-
dissolving/disintegrating tablet formulation. DuraSolv 
has much higher mechanical strength than Orasolv due 
to the use of higher compaction pressures during 
tableting. DuraSolv product is thus produced in a 
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faster and more cost-effective manner. DuraSolv is so 
durable that it can be packaged in either traditional 
blister packaging or vials. This technology is not 
compatible with larger doses of active ingredients, 
because the formulation is subjected to such high 
pressures on compaction. Unlike OraSolv, the 
structural integrity of any taste masking may be 
compromised with high drug doses. The drug powder 
coating in DuraSolv may become fractured during 
compaction, exposing the bitter-tasting drug to a 
patient's taste buds. Therefore, DuraSolv technology is 
best suited for formulations including relatively small 
doses of active compound. The tablets made by this 
technology consist of a drug, fillers and a lubricant and 
prepared by using conventional tableting equipment 
and have good rigidity. These can be packed into 
conventional packaging system like blisters. Due to 
higher force of compaction used, tablets prepared are 
rigid. 
 
Orasolv (Cima Labs, Inc.) (17) 
Orasolv® is Cima’s first orally disintegrating dosage 
form. It based on direct compression of an effervescent 
agent and taste masked drug. The use of effervescence 
causes a tablet to disintegrate rapidly in less than 1 min 
on contact with water or saliva leaving coated drug 
powder. This technique is frequently used to develop 
over the counter formulations. This technology can 
accommodate a wide range of active ingredient from 
1 mg to 500 mg. The effervescence occurs due to 
chemical reaction between organic acid such as citric 
acid, fumaric acid or maleic acid and a base such as 
sodium bicarbonate, potassium bicarbonate, 
magnesium bicarbonate, which result in generation of 
CO2.  
 
Effervescent disintegration agents evolve gas by 
means of chemical reaction called effervescent couple. 
Carbonates such as sodium bicarbonate, sodium 
carbonate, potassium bicarbonate and potassium 
carbonate, magnesium carbonate, and acids like citric, 
tartaric, fumaric, adipic and succinic are used. 
Microparticles, effervescent agents and other 
ingredient such as flavors, sweeteners, colorants and 
lubricants are blended and compressed at a low degree 
of compaction.  
 
Frosta (Akina) (19) 
It utilizes the concept of formulating plastic granules 
and compressing them at low pressure to produce 
strong tablets with high porosity. Plastic granules 
composed of porous and plastic material, water 
penetration enhancer, and binder. The process 
involves mixing the porous plastic material with water 
penetration enhancer followed by granulating with 
binder. The tablets obtained have excellent hardness 
and rapid disintegration time ranging from 15 to 30 sec 
depending on size of tablet.  
 
Flashdose (Fuisz Technologies, Ltd.)(13).(14)  
This technology is patented by Fuisz. This uses the 
combination of Shearform and Ceform technologies in 
order to mask the bitter taste of the drug.  
 
A sugar based matrix, called ‘Floss’, which is made up 
of a combination of crystalline sugars alone or in 
combination with drugs, is used. Floss is self binding 
shearform matrix, which is prepared by flash heat 
processing. FlashDose technology utilizes a unique 
spinning mechanism to produce a floss-like crystalline 
structure, much like cotton candy. This crystalline 
sugar can then incorporate the active drug and be 
compressed into a tablet. This procedure has been 
patented by Fuisz and is known as Shearform. It 
disperses and dissolves quickly. The method has 
certain drawbacks like the dosage form can 
accommodate only up to 600 mg of drug and tablets 
required specialized packing as highly friable, soft and 
moisture sensitive nature.  
 
Instead of a floss-like material, small spheres of 
saccharides can be produced to carry the drug. The 
process of making microspheres has been patented by 
Fuisz, and is known as Ceform and serves as an 
alternative method of taste masking. Ceform 
technology involves preparation of microspheres of 
the active drug. Drug material alone or in combination 
with other pharmaceutical substances, and excipients 
is placed into a rapidly spinning machine. The 
centrifugal force comes into action, which throws the 
dry drug blend at high speed through small heated 
openings. Due to the heat provided by carefully 
controlled temperature, drug blend liquefies to form a 
sphere, without affecting the drug stability. The 
formed microspheres are compressed into tablet. This 
technique effectively masked the taste of product. 
 
OraQuick (KV Pharmaceutical Co., Inc.) (20) 
OraQuick utilizes its own patented taste masking 
technology i.e. MicroMask®. In MicroMask® 
technology, taste masking process is done by 
incorporating drug into matrix microsphere. In this 
technique, tablet is prepared by dissolving the sugar 
(sucrose, mannitol, sorbitol, xylose, dextrose, fructose 
or mannose) and protein (albumin or gelatin) in a 
suitable solvent such as water, ethanol, isoproryl 
alcohol and ethanol-water mixture. The solution of 
matrix is then spray dried, yielding highly porous 
granules. Also, utilization of lower heat of production 
is advantageous for heat-sensitive drugs. Granules 
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formed then mixed with drug and other excipients and 
compressed at low compression force. KV 
pharmaceuticals claimed that matrix formed protects 
and surrounds the drug powder in microencapsulated 
particles is more reliable during this step.  
 
Nanocrystal Technology (Elan corporation) (21), (23) 
This technology is based on concept that decreasing 
particle size increases the surface area, which leads to 
an increase in dissolution rate. NanoCrystal particles 
are small particles of drug substance, typically less 
than 1000 nm in diameter, which are produced by wet 
milling the drug.  
 
NanoCrystal™ fast dissolving technology provides 
for:  
• Pharmacokinetic benefits of orally 
administered nanoparticles (<2 microns) in the form of 
a rapidly disintegrating tablet matrix.  
• Product differentiation based upon a 
combination of proprietary and patent-protected 
technology elements.  
• Cost-effective manufacturing processes that 
utilize conventional, scalable unit operations.  
• Exceptional durability, enabling use of 
conventional packaging equipment and formats (i.e., 
bottles and/or blisters).  
• Wide range of doses (up to 200mg of API per 
unit).  
• Utilization of non-moisture sensitive 
inactives.  
 
Quick-Dis Technology (Lavipharm) (24) 
Lavipharm Laboratories Inc. has invented an ideal 
intraoral fast-dissolving drug delivery system called as 
Quick-Dis™. This is a thin, flexible, and quick-
dissolving film. The film is placed on the top or the 
floor of the tongue. It is retained at the site of 
application and rapidly releases the active agent for 
local and/or systemic absorption. The Quick-Dis™ 
drug delivery system can be provided in various 
packaging configurations, ranging from unit-dose 
pouches to multiple-dose blister packages. 
Disintegration time is only 5 to 10 seconds for the 
Quick-Dis™ film with a thickness of 2 mm. The 
dissolving time, which is defined as the time at which 
not less than 80% of the tested film is dissolved in 
aqueous media, is around 30 seconds for Quick Dis™ 
film with a thickness of 2 mm. The typical release 
profile of an active ingredient exhibited by a Quick-
Dis™ drug delivery system is 50% released within 30 
seconds and 95% within 1 minute [46].  
 
EFVDAS (Elan Corporation) (23) 
EFVDAS or Effervescent Drug Absorption System is 
a drug delivery technology that has been used in the 
development of a number of both OTC and 
prescription medications. This is particularly 
advantageous for conditions such as colds and flu, for 
which Elan has modified its EFVDAS technology to 
develop hot drink sachet products that combine 
medicines and vitamins for OTC use. The granular 
contents of the sachets can be added to boiling water 
to produce pleasant-flavored solutions. In these cases 
the effervescence of the granulate mixture is modified 
to accommodate the use of heated water. Examples of 
products that Elan has developed include effervescent 
ibuprofen, acetaminophen, cimetidine, naproxen, and 
acetaminophen and codeine combination product.   
 
Fast Melt (Elan Corporation) (16),(15) 
It is a highly porous, microfine matrix tablet. Once 
placed on the tongue, this matrix rapidly absorbs liquid 
and disintegrates. The drug, in a stabilized, size-
reduced form to ensure optimal solubility, dissolves 
rapidly. The combination of a mild effervescent base 
and drug processing ensures that the dosage form goes 
into solution in approximately 15 to 30 seconds. The 
drug is released rapidly within the oral cavity, where it 
dissolves to form a drug solution that is then 
swallowed. This is particularly advantageous in cases 
like migraine where a fast onset of clinical effect is 
required. A portion of the drug solution may be 
absorbed locally in the oral cavity and therefore may 
avoid first-pass metabolism in the liver that limits the 
bioavailability of many drugs. The fast-melt system 
rapidly disintegrates in the oral cavity; hence, patients 
do not have to swallow a large cumbersome dosage 
form, which discourages many from taking their 
medication. Thus, the fast-melt dosage form combines 
the benefits of liquid formulations with those of a solid 
oral dosage form. 
 
Multiflash (Prographarm) (18) 
Multiflash is a multi-unit tablet composed of coated 
microgranules and fast-disintegrating excipients. This 
multiparticulate tablet quickly disintegrates in the 
esophagus after being swallowed with a minimum 
amount of water. This tablet avoids mucosal adhesion, 
and coated pellets can match various dissolution rates.  
 
Cotton candy process(21)  
This process based on formation of matrix of 
polysaccharides or saccharides which are partially 
recrystallized and attain better flow properties and 
compressibility by concurrent action of flash melting 
and spinning. Then matrix is milled and blended with 
active ingredients and excipients, soon after 
compressed to form tablets. 
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Direct compression (20) 
The basic principle of this technique is addition of 
superdisintegrants in optimum concentrations to tablet 
formulation in which powdered blend compress 
directly to form tablets. 
 
CONCLUSION: 
As a conclusion orally disintegrating tablets have 
many advantages compared with the other oral dosage 
forms, such as better bioavailability, better patient 
compliance, and improved efficacy. Nevertheless 
formulation challenges such as limited tablet weight, 
disintegration time, friability, manufacturing 
technology, and packaging should be considered. 
Orally disintegrating tablets may be evaluated as a first 
choice for pediatrics and geriatrics –situations that 
parenteral cannot be used especially for central 
nervous system, gastrointestinal system disorders and 
pain. 
 
This dosage form has been formulated for existing 
drugs for extending the patent life of the drug and also 
for granting the new patent. Majority of drugs can be 
formulated as orodispersible tablets. The safety and 
efficacy profile of drugs in orodispersible tablet is 
same like their conventional tablet dosage form. Based 
on conventional techniques, new techniques are 
developed like Zydis, WowTab, Orasolv and many 
more, which leads to getting a patent and new market 
strategy for orodispersible tablets. This dosage form 
are gaining market share day by day and becoming a 
better choice of acceptance. 
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